Literature DB >> 7281501

Hepatic glomerulonephritis. Characteristics of hepatic IgA glomerulonephritis as the major part.

Y Nakamoto, H Iida, K Kobayashi, K Dohi, H Kida, N Hattori, J Takeuchi.   

Abstract

Glomerular lesions associated with hepatic disease were evaluated. Among 752 consecutive patients with hepatitis and cirrhosis, nephritic urinary changes appeared in 1.0% of chronic hepatitis and 9.2% of cirrhotics, but none in patients with acute or subacute hepatitis. Kidney tissue was obtained from 141 cases, of which 59 underwent immunofluorescent studies. Except for a few with possibly coincidental glomerulonephritis, the main glomerular pathology was mesangial depositive or proliferative lesions with frequent circumferential mesangial interposition. The highest incidence (up to 69.2%) occurred in liver cirrhosis. The glomerular immunohistology was not necessarily homogeneous. In acute or subacute hepatitis, IgG or IgM, if present, was dominant. The more chronic the course the liver disease followed, the more frequently significant IgA deposition emerged, occurring in 60.5% of cirrhotics. The IgA positive cases often disclosed paramesangial dense deposits, which is one of the characteristics of primary IgA nephritis. Hepatic IgA nephritis exhibited a lower nephritogenicity and a proneness to show mesangial interposition when compared with primary or purpuric IgA nephritis. The possible origin of glomerular IgA associated with liver disease is discussed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7281501     DOI: 10.1007/BF00430547

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histol        ISSN: 0340-1227


  30 in total

1.  Renal lesions in portal cirrhosis.

Authors:  J H BAXTER; C T ASHWORTH
Journal:  Arch Pathol (Chic)       Date:  1946-05

2.  Intercapillary Glomerulosclerosis.

Authors:  R C Horn; H Smetana
Journal:  Am J Pathol       Date:  1942-01       Impact factor: 4.307

3.  [Glomerulonephritis with diffuse IgA deposits in the mesangium. Study of 96 adult cases].

Authors:  P de Werra; L Morel-Maroger; C Leroux-Robert; G Richet
Journal:  Schweiz Med Wochenschr       Date:  1973-05-26

4.  Glomerular abnormalities in nonsystemic diseases. Relationship between findings by light microscopy and immunofluorescence in 433 renal biopsy specimens.

Authors:  L Morel-Maroger; A Leathem; G Richet
Journal:  Am J Med       Date:  1972-08       Impact factor: 4.965

5.  Antibodies to intestinal microbes in serum of patients with cirrhosis of the liver.

Authors:  M Bjorneboe; H Prytz; F Orskov
Journal:  Lancet       Date:  1972-01-08       Impact factor: 79.321

6.  Bacterial and dietary antibodies in liver disease.

Authors:  D R Triger; M H Alp; R Wright
Journal:  Lancet       Date:  1972-01-08       Impact factor: 79.321

7.  [Intercapillary glomerulosclerosis in hepatic cirrhosis (author's transl)].

Authors:  H Wehner; D Andler
Journal:  Virchows Arch A Pathol Pathol Anat       Date:  1973-09-04

8.  Primary IgA glomerulonephritis and Schönlein-Henoch purpura nephritis: Clinicopathological and immunohistological characteristics.

Authors:  Y Nakamoto; Y Asano; K Dohi; M Fujioka; H Iida; H Kida; Y Kibe; N Hattori; J Takeuchi
Journal:  Q J Med       Date:  1978-10

9.  Alcoholic hepatic disease. Specificity of IgA deposits in liver.

Authors:  L Kater; A C Jöbsis; E H de la Faille-Kuyper; A J Vogten; R Grijm
Journal:  Am J Clin Pathol       Date:  1979-01       Impact factor: 2.493

10.  Complement deficiency and nephritis. A report of a family.

Authors:  B A Pussell; E Bourke; M Nayef; S Morris; D K Peters
Journal:  Lancet       Date:  1980-03-29       Impact factor: 79.321

View more
  12 in total

1.  [Alcohol and IgA in the kidney].

Authors:  H Köhler
Journal:  Klin Wochenschr       Date:  1985-09-16

2.  [Kidney involvement in liver diseases: morphology].

Authors:  G Syré
Journal:  Klin Wochenschr       Date:  1983-10-17

3.  Glomerulonephritis as late manifestation of severe alpha 1-antitrypsin deficiency.

Authors:  R E Stauber; J H Horina; M Trauner; G J Krejs; M Ratschek; M Klimpfinger
Journal:  Clin Investig       Date:  1994-05

4.  Association of liver cirrhosis related IgA nephropathy with portal hypertension.

Authors:  Georgios Kalambokis; Leonidas Christou; Dimitrios Stefanou; Evdokia Arkoumani; Epameinondas V Tsianos
Journal:  World J Gastroenterol       Date:  2007-11-21       Impact factor: 5.742

5.  Glomerular abnormalities in children undergoing orthotopic liver transplantation.

Authors:  S E Chin; R A Axelsen; D H Crawford; Z H Endre; S V Lynch; G A Balderson; R W Strong; R W Shepherd; J R Burke; S J Fleming
Journal:  Pediatr Nephrol       Date:  1992-09       Impact factor: 3.714

6.  IgA nephropathy in non-cirrhotic portal hypertension.

Authors:  C Babbs; T W Warnes; H B Torrance; F W Ballardie
Journal:  Gut       Date:  1991-02       Impact factor: 23.059

7.  Immune complex nephritis in alcoholic cirrhosis: detection of Mallory body antigen in complexes by means of monoclonal antibodies to Mallory bodies.

Authors:  J Burns; A J D'Ardenne; J A Morton; J O McGee
Journal:  J Clin Pathol       Date:  1983-07       Impact factor: 3.411

8.  Sofosbuvir and ledipasvir decreased nephrotic syndrome caused by IgA nephropathy with a membranoproliferative pattern of injury in hepatitis C virus-induced cirrhosis: a case report.

Authors:  Xiaohao Zhang; Jing Zhou; Canming Li; Jialing Rao; Yuanqing Li; Jun Zhang; Hui Peng
Journal:  Ann Transl Med       Date:  2022-04

9.  Uncoupling of glomerular IgA deposition and disease progression in alymphoplasia mice with IgA nephropathy.

Authors:  Masashi Aizawa; Yusuke Suzuki; Hitoshi Suzuki; Huihua Pang; Masao Kihara; Junichiro Nakata; Kenji Yamaji; Satoshi Horikoshi; Yasuhiko Tomino
Journal:  PLoS One       Date:  2014-04-17       Impact factor: 3.240

10.  Acute glomerulonephritis with large confluent IgA-dominant deposits associated with liver cirrhosis.

Authors:  Jessica Hemminger; Vidya Arole; Isabelle Ayoub; Sergey V Brodsky; Tibor Nadasdy; Anjali A Satoskar
Journal:  PLoS One       Date:  2018-04-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.